Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03745638 · ClinicalTrials.gov registry record · Phase 3
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis
A Phase 3 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 631
- Enrollment target
NCT03745638 is a Phase 3 study that has completed, run by Incyte Corporation. The registered enrollment target is 631 participants.
The verdict
NCT03745638, a Phase 3 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 631 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of twice daily ruxolitinib cream in adolescents and adults with Atopic Dermatitis (AD).
Interventions
- DRUG Ruxolitinib Cream
- DRUG Vehicle Cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 631 participants |
| Start Date | 2018-12-20 |
| Est. Completion | 2020-12-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03745638
The ClinicalTrials.gov registry entry for NCT03745638 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 631 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ruxolitinib Cream is the first listed.
NCT03745638 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03745638 about?
NCT03745638 is a clinical study titled "Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis". The purpose of this study is to assess the efficacy and safety of twice daily ruxolitinib cream in adolescents and adults with Atopic Dermatitis (AD).
What is the current status of trial NCT03745638?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 631 participants. The study started on 2018-12-20. Estimated completion is 2020-12-01.
What interventions are being tested in trial NCT03745638?
The interventions under investigation include: Ruxolitinib Cream (DRUG), Vehicle Cream (DRUG).
Who is sponsoring clinical trial NCT03745638?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.